Table 1.
Baseline characteristics and outcomes of patients enrolled in CP-Kp outbreak.
| Patient | Isolate | Gender | Age | Underlying diseases | Sample date since admission(d) | Culture Site | Treatment therapy* | Glucocorticoids use before culturing positive | Outcome | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|
| Pt-1 | KP-s1 | M | 45 | H7N9 influenza A infection | 8 | Blood | MEM, TIG, FOS, MIF | Yes | Improved | / |
| Pt-2 | KP-s2 | M | 65 | Severe pneumonia | 12 | Sputum | MEM, TIG, AMI, LZD, VRC, CRO | No | Died | CP-kp infection |
| Pt-3 | KP-s3 | M | 51 | Hepatitis B; decompensated liver cirrhosis | 25 | Blood | TZP, AMI, LEV | Yes | Improved | / |
| Pt-4 | KP-s4 | F | 52 | Severe pneumonia | 2 | Sputum | I/C, VAN, MXF, CAS | No | Improved | / |
| Pt-5 | KP-s5 | F | 35 | Central nervous system infection | 29 | Urine | MEM, LZD, INH, RFP, PZA, EMB | Yes | Died | Central nervous system infection |
| KP-s6 | Sputum | |||||||||
| Pt-6 | KP-s7 | M | 30 | Acute on chronic liver failure | 12 | Blood | MEM, AMI, FOS, TIG, CAS, MIF | Yes | Improved | / |
| Pt-7 | KP-s8 | M | 54 | Acute on chronic liver failure | 24 | Urine | MEM, LZD, MXF, MIF | Yes | Died | CP-kp infection |
| Pt-8 | KP-s9 | M | 73 | Acute severe hepatitis E | 43 | Exudate | MEM,MXF,TIG,FOS,CAS,MIF | Yes | Died | CP-kp infection |
*
AMI, Amikacin; CRO, Ceftriaxone; TZP, Piperacillin/tazobactam; LEV, Levofloxacin; MXF, Moxifloxacin; I/C, Imipenem/cilastatin; MEM, Meropenem; FOS, Fosfomycin; TIG, Tigecycline; VAN, Vancomycin; LZD, linezolid; VRC, Voriconazole; MIF, Micafungin; CAS, Caspofungin; INH, Isoniazid; RFP, Rifampicin; PZA, Pyrazinamide; EMB, Ethambutol.